All,

Forwarding the CMS announcement on Medicare coverage of COVID 19 antibody treatment.

 

Ann

 

From: CMS Office of Communications <xxxxxx@cms.hhs.gov>
Sent: Wednesday, December 9, 2020 5:30 PM
To: Ann Kayrish <xxxxxx@ncoa.org>
Subject: CMS announces guidance for Medicare coverage of COVID-19 antibody treatment

 

Caution. This email is EXTERNAL.

Image removed by sender.

CMS announces guidance for Medicare coverage of COVID-19 antibody treatment

 

 

Date: December 9, 2020

 

Contact: CMS Media Relations

(202) 690-6145 | CMS Media Inquiries

 

 

 

Today, the Centers for Medicare & Medicaid Services (CMS) posted updates to FAQs and an infographic about coverage and payment for monoclonal antibodies to treat coronavirus disease 2019 (COVID-19). The FAQs include general payment and billing guidance for these products, including questions on different setting types. The infographic has key facts about expected Medicare payment to providers and information about how Medicare beneficiaries can receive these innovative COVID-19 treatments with no cost-sharing during the public health emergency (PHE). CMS’ November 10, 2020 announcement about coverage of monoclonal antibody therapies allows a broad range of providers and suppliers, including freestanding and hospital-based infusion centers, home health agencies, nursing homes, and entities with whom nursing homes contract, to administer this treatment in accordance with the Food & Drug Administration’s Emergency Use Authorization (EUA), and bill Medicare to administer these infusions. Currently, two monoclonal antibody therapies have received EUA’s for treatment of COVID-19.

 

For more information about billing and payment for COVID-19 monoclonal antibody treatments, please see Section BB of the FAQs here: 

https://www.cms.gov/files/document/03092020-covid-19-faqs-508.pdf

 

 

Monoclonal toolkit and program guidance can be found here:

https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion

 

 

The Therapeutics Coverage Infographic can be found here:

https://www.cms.gov/files/document/covid-infographic-coverage-monoclonal-antibody-products-treat-covid-19.pdf

 

 

###

 

 

Get CMS news at cms.gov/newsroom, sign up for CMS news via email and follow CMS on Twitter CMS Administrator @SeemaCMS and @CMSgov

The information contained in this electronic mail and its attachments is privileged and confidential. It is intended for the use of the addressee and others specifically authorized to receive it. If you are not the intended recipient, you are prohibited from disseminating, distributing or copying this communication. If you have received this e-mail in error, please delete it and notify us by replying to this e-mail immediately.

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by Mimecast Ltd, an innovator in Software as a Service (SaaS) for business. Providing a safer and more useful place for your human generated data. Specializing in; Security, archiving and compliance. To find out more Click Here.